Xavier Duportet

Nice opportunity to learn more about Biomunex #bispecifics Platform and how MAIT Engagers, an abundant cytotoxic T-cell subset, can play a role in solid tumors treatment #FestivalofBiologics

4

Bold and brave by Jubilant Biosys Limited ! 🇮🇳 Perhaps a little misplaced, but ever since the Eli Lilly/Covance Greenfield site deal (can you believe that was 16 years ago?!) I have a certain fondness for this type of agreement, where significant site and domain expertise is not lost in the name of cost control, but instead pivoted from serving the internal needs of a pharma company to face the broader external market as part of a CRO.... ....maybe I'm being idealistic, but beyond the jobs being secured I think I like the sense of parity such deals suggests, that both sponsor and CRO are genuine piers/partners with the shared goal of improving human health driving both sides of the relationship....i.e. in the end, does it really matter which side of the fence you're on?.....(or am I just being a bit romantic....these deals seem to be very popular in France... 🇫🇷 🥂 ) In any case, this seems to me to be a significant deal in that: 1) It brings a serious Indian based Integrated Drug Discovery (IDD) player to the heart of Europe and with a scaled and mature offering. 2) It brings Jubilant straight into the ADC/biologics space, complimenting traditional small molecule expertise. 3) At the flick of a switch it brings new capacity, expertise and capabilities to the European CRO market. In the longer run I guess the challenge will be ensuring that there is sufficient revenue coming to the site if/when Pierre Fabre (inevitably?) scale back once their initial commitment has run down... (as a comparison, GSK committed to $40M over 4 years to Oncodesign Services as part of the deal transferring the Les Ulis site....certainly helps cover the costs for a while...!) But that's a question for tomorrow....for today, congratulations to Giuliano Perfetti and the Jubilant team!

7

🪴#Biocontrol and #Biostimulants: What are the effects on vines? 🌿 💡 In November 2023, Vitagora hosted an insightful workshop in Montpellier, South of France, on the topic: “Biocontrol and Biostimulants: What Are the Effects on Vines?”. This event brought together experts and industry professionals to explore the latest findings on how biocontrol and biostimulant solutions impact vine health and productivity. The Institut français de la vigne et du vin (IFV) a leading technical institute dedicated to innovative research in viticulture, which is key to advancing sustainable practices in the wine industry. As a key partner in the Novaterra project, IFV conducted experimental trials on #nanoparticles and bio-solutions, with results highlighting the efficacy of sulfur as a #sustainable solution. Watch the interview: https://lnkd.in/erHuzPgg #innovation #sustainableagriculture #pesticides Guillaume Delanoue SITEVI

4

Scientists at Massachusetts Institute of Technology introduce #AbMAP: a cutting-edge method for precise 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗺𝗼𝗱𝗲𝗹𝗶𝗻𝗴! 🧬 Using contrastive augmentation and multitask learning, 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗠𝘂𝘁𝗮𝗴𝗲𝗻𝗲𝘀𝗶𝘀-𝗔𝘂𝗴𝗺𝗲𝗻𝘁𝗲𝗱 𝗣𝗿𝗼𝗰𝗲𝘀𝘀𝗶𝗻𝗴 (𝗔𝗯𝗠𝗔𝗣) significantly improves predictions of key antibody properties, such as antigen binding and paratope identification. With an impressive 82% hit rate in optimizing SARS-CoV-2-binding antibodies, it’s redefining antibody design and therapeutic discovery. Could this reshape drug discovery? 🧬💉 Quick Read: https://lnkd.in/gcCmJbwM #Bioinformatics #AntibodyResearch #AIinScience #Immunology #DrugDiscovery #ScienceNews

7

📣 Elikya Therapeutics, a company of the Landmark BioVentures AG nexus, and spinoff from the Gustave Roussy institute and Université Paris-Saclay showcased its ground-breaking new technology focusing on toxic payloads for Antibody Drug Conjugates (#ADCs) at the prestigious pitch studio of Gustave Roussy during Viva Technology 2024, the biggest tech and healthtech event in Europe. Elikya Therapeutics is focused on the development of next Generation of ADCs using its First-in-Class toxic payload, with a unique mode of able to address tumor and its microenvironment in parallel, and with a long-standing memory immune response. Elikya's unique approach focuses also on the development of Precision Conjugates: considering that new ADCs shall be designed on the comprehensive mechanistic properties of the payload (payload centric design) Elikya Therapeutics Quest for health Gary Brandam Zaki Sellam Bpifrance Dr Jacques-Alain Bauer Mouad Alami sebastien apcher

37

2 Comments

What if everyone could raise funds 💰? Would the world 🌎 be a better place ? As a biotech CEO, I often think about the role of financing in innovation, particularly for Seekyo Therapeutics. If every entrepreneur succeeded in raising capital, we would undoubtedly see more solutions tackling some of humanity’s biggest challenges—especially in healthcare. Promising technologies would move faster, and more ideas 💡 would have a shot at transforming lives. But here’s the reality: funding is just the beginning. Having money doesn’t guarantee success. In biotech, the real battle lies in the lab and through clinical trials. The science must work. Either your solution delivers on its promise, or it doesn’t—regardless of how well-funded you are. From an ideal macroeconomic perspective, a world where everyone could secure investment could lead to a surge in innovation, job creation, and economic growth. However, it could also introduce inefficiencies. Not every idea should be funded. Capital allocated to weak or poorly executed projects could undermine resources available for truly transformative innovations. So, the question isn’t just, “Can you raise funds?” It’s also, “What will you do with them?” Capital alone doesn’t change the world—execution, resilience, and results do. What’s your take?

19

5 Comments

🔬 **Micropatterned Biology : Revolutionizing Biological Research** 🌟 What a publication from Oujiang laboratory in China with massive references to the big guy @Manuel thery from CEA in Feance. An impressive Review that explores all the aspect of micro patterning and the wide range of applications. Explore and discover how micropatterning is paving the way for new innovations in biotechnology! - **Unmatched Precision**: Precise manipulation of cell adhesion proteins on various substrates. - **Advanced Control**: Mastery of architectures and physical constraints for single or multiple cells. - **In-depth Analysis**: Detailed study of the impact of chemical and physical properties on cellular functionality. - **Innovative Approach**: Utilizing directed self-organization through morphogen gradients on micropatterned surfaces. - **Wide Applications**: Generation of functional tissues and control of morphogenesis in vitro for the future of In vitro models and NAM’s. By combining micropatterning with cutting-edge technologies as PRIMO Alvéole we can bridge a crucial knowledge gap in understanding fundamental biological processes. 💡✨ #Innovation #Biotechnology #Micropatterning #Research #Science #Technology #NAM https://lnkd.in/etFNTXT2

20

Kudos to Debiopharm! But the problem of silos remains, certainly in big companies. IMHO, the root cause has to do with communication between different stakeholders, at the very basic level of the words that are being used. They are either imprecise and ambiguous ( e.g. "inflammation" ") and/or mean different things to different stakeholders (ask a clinical oncologist, a GP or a cancer biologist to give you a clear definition of "cancer"). When different experts meet to discuss, they may use the same words but the meaning is not the same. There is a disconnect.... and no one is truly aware of it... This leads to quid pro quos, silos and sometimes catastrophic outcomes. I have seen it over and over again in my 20 years of teaching biotech to all non-biologists... A standardized, controlled vocabulary, or ontology, is crucial to ensure clear communication and collaboration across all functions. I have nailed it down, at least version 1.0, thanks to my 3000 students representing all functions in the pharma industry. I'd love to publish what I have as an online interactive glossary where each term becomes an item of actionable knowledge. But I need help and some funding. Anyone out there interested?

3

1 Comment

Skin penetration is critical in skincare because actives must reach the deeper layers to impact cells and deliver real results. 🌱 Most ingredients remain superficial, rendering them ineffective, but Core Biogenesis has achieved a breakthrough in skincare with its Oleosome-Protein fusion technology, delivering peptides and proteins deep into the dermis—a feat most actives fail to accomplish due to instability and poor penetration. Using our plant-based biofactory platform, we stabilize actives up to 10x and ensure effective delivery beyond the epidermis, unlocking new efficacy benchmarks. 💫

20

👉 GoLiver Therapeutics has been awarded €1.6m from France 2030 to progress its first biomedicine, developed from pluripotent stem cells, into the clinic for the treatment of severe liver failures.   For Tuan Huy Nguyen, President of GoLiver Therapeutics : « We are very grateful to France 2030 for supporting us in reaching a major milestone for our first advanced cell drug candidate. The GOCLINICALS project will reveal our technological lead. GoLiver Therapeutics will be the first company to conduct a clinical trial of liver regenerative medicine using pluripotent stem cells. GLTX-001 will be a game-changer for patients suffering from liver disease. The preclinical data is impressive, and the fact that it can be made available immediately, in unlimited quantities and ready-to-use are already factors for its success in routine clinical use »   👉 For more information : https://lnkd.in/exyCKQtX

160

34 Comments

This is a fascinating paper discussing the creation of LifeWatch ERIC, a #BioDT partner and research infrastructure. Learn about why research infrastructures like this are essential to the creation of a prototype #digitaltwin on our website: https://lnkd.in/ecyuXj7f Read the full article: https://lnkd.in/evvy2rbk

7

BioSciTech BiWeekly Newsletter: 15 May 2024 Issue:   COMMENTARY & NEWS Interview with Dr. Yasmine Belkaid President of Institut Pasteur, Université Paris-Saclay, Paris, Île-de-France, France https://lnkd.in/eEuqpU4T   Biotech news from around the world https://lnkd.in/emm_sF22 Top companies and drugs by sales in 2023 By Paul Verdin https://lnkd.in/ekkaxMxs   Retractions are part of science, but misconduct isn’t — lessons from a superconductivity lab https://lnkd.in/exeX8ZYa African Population and Health Research Center http://www.aphrc.org   RECOMMENDED PUBLICATIONS Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses Rashmi Ray, Faez Amokrane Nai et al., 2024 https://lnkd.in/eHjMBTjH Life-saving effect of pulmonary surfactant in premature babies Raj et al., 2024 J Clin Invest. 2024;134(9):e179948. https://lnkd.in/eXXDr4Md. An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis Lee et al., 2024 J Clin Invest. 2024;134(9):e173371. https://lnkd.in/eBt9wVkJ. Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase Baltgalvis et al., 2024 https://lnkd.in/eNSAq46b T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy Guido Ghilardi, et al., 2024 https://lnkd.in/eKSCWwaF   The plant immune system: From discovery to deployment Jones et al., 2024. https://lnkd.in/ezgG2pjA Accurate structure prediction of biomolecular interactions with AlphaFold 3 Abramson et al., 2024 https://lnkd.in/e7FgNwQ3 Probing the CRL4DCAF12 interactions with MAGEA3 and CCT5 di-Glu C-terminal degrons Lima et al., 2024 https://lnkd.in/ehqDNQj7 RECOMMENDED EVENTS The transformative role of AI in revolutionising drug discovery? ELRIG https://lnkd.in/eNBiKiHr The 2nd call for papers for the 12th European Workshop on Visual Information Organized by Prof. Habib Zaidi, Head of PET Instrumentation & Neuroimaging Laboratory (PINLab), Geneva University Hospital, Department of Diagnostics, Switzerland Access Registration & Program: https://www.euvip2024.org/ Reinventing Drug Discovery, from Retrospective to Perspectives 10th NovAliX Conference - Anniversary Edition Brunnen, Switzerland   June 2-4, 2024 VIRTUAL REGISTRATION NOW OPEN! https://lnkd.in/eAf2QQ7R

25

Discover the future of #biotechnology! Dive into the revolutionary world of #organoid research with Nicolas Aznar, Jerome Sohier and Lucas Lemarié in Lyon, France. Discover how Mimix Biotherapeutics' revolutionary SIM (Sound Induced Morphogenesis) technology is transforming the landscape of scientific exploration. Curious to discover the synergy between sound waves and tissue development? Don't miss this exciting journey into the orchestration of #biology. #organoids #lifescience #stemcells

30

🌿In 2022, plastic production hit 400 million tons, with much ending up as waste. CARBIOS and the TBI - Toulouse Biotechnology Institute, Bio & Chemical Engineering are changing the game with a new enzyme-embedded PLA plastic that rapidly biodegrades at room temperature! 🔬Thanks to groundbreaking research and collaboration with ESRF - The European Synchrotron, this innovative material meets home composting standards and enhances biomethane production. It's a major leap for sustainable packaging and single-use items. 💡Emmanuel LADENT 🌏 CEO CARBIOS said: "As #Carbios expands its portfolio of enzymatic solutions beyond PET, enzyme-embedded PLA represents a major leap forward, addressing a critical gap in the market for compostable plastic." The results are published in #Nature👉 https://bit.ly/3WCDE9Y #Sustainability #Innovation #Biodegradable #CircularEconomy #ESRF 🖼️ 𝘛𝘩𝘦 𝘦𝘯𝘤𝘢𝘱𝘴𝘶𝘭𝘢𝘵𝘦𝘥 𝘦𝘯𝘻𝘺𝘮𝘦 𝘊𝘈𝘙𝘉𝘐𝘖𝘚 𝘈𝘤𝘵𝘪𝘷𝘦, 𝘪𝘯 𝘨𝘳𝘢𝘯𝘶𝘭𝘦 𝘧𝘰𝘳𝘮, 𝘸𝘩𝘦𝘯 𝘪𝘯𝘵𝘦𝘨𝘳𝘢𝘵𝘦𝘥 𝘥𝘪𝘳𝘦𝘤𝘵𝘭𝘺 𝘪𝘯𝘵𝘰 𝘗𝘓𝘈-𝘣𝘢𝘴𝘦𝘥 𝘱𝘢𝘤𝘬𝘢𝘨𝘪𝘯𝘨 𝘰𝘳 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴 𝘢𝘵 𝘵𝘩𝘦 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘪𝘰𝘯 𝘱𝘩𝘢𝘴𝘦, 𝘦𝘯𝘢𝘣𝘭𝘦𝘴 𝘤𝘰𝘮𝘱𝘰𝘴𝘵𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘢𝘵 𝘳𝘰𝘰𝘮 𝘵𝘦𝘮𝘱𝘦𝘳𝘢𝘵𝘶𝘳𝘦⬇️

24

1 Comment

What's next for cell and gene therapies ? I had the pleasure to participate this rich panel discussion animated by Megan Thomas at #anglonordic conference today together with SpliceBio, Illumina Ventures and M Ventures. The conversation reflected the challenges the field faced and still needs to solve, but also the great  achievements that were accomplished and lie ahead.  Solutions are in development and being invested in, now collaboration will be instrumental to build a next generation of cell and gene therapies that will not only be safe and efficacious, but also economically viable and scalable.

93

3 Comments

🎥 Video of the Week from #ODSCWest! Dive into the cutting edge of AI and synthetic biology with Etienne Goffinet, PhD, Senior Researcher at the Technology Innovation Institute, in his session: Introduction to Protein Language Models for Synthetic Biology. Key highlights: 🔸Understand how Protein Language Models mimic natural language models to learn the 'grammar' of proteins. 🔸Explore open-source tools and datasets for building protein models. 🔸Learn how to classify protein functions with practical hands-on examples. 🔸Benchmark various approaches, from retrieval-augmented techniques to fine-tuning pre-trained models. Whether you're a bioinformatics enthusiast, machine learning practitioner, or simply curious about the intersection of AI and biology, this talk offers invaluable insights into leveraging Transformer-like models for groundbreaking research. 🔗 https://hubs.li/Q030v3Rz0 #AI #SyntheticBiology #ProteinLanguageModels #ODSC

2

I am delighted to announce you that Weo’s research about senescence and anti-aging properties of Weo Water has been published yesterday in the very serious journal Aging (Aging-US) It is the result of our vision on the anti-aging properties of Weo water and of three years of diligent and very high-level research from our team (list below) and directed together with Pierre-Yves Desprez, Director of Research, from the Buck Institute for Research on Aging in #SanFrancisco (leader in #Aging related #research). Here’s an excerpt if you do not wish to read-it all: “… suggests that WEW (Weo Electrolyzed Water) acts as a protective factor, thereby reducing oxidative stress in normal cells, while making cancer cells more sensitive to the effects of cellular stress, thus increasing their elimination and consequently reducing their deleterious effects. These findings suggest that, due to its differential effects as a senomorphic factor, WEW (Weo Electrolyzed Water) could have a positive impact on longevity and age-related diseases.” This very exciting and valuable paper is more than an achievement. It is the demonstration of the incredible properties of our #technology and of the #water Weo is capable of offering. This milestone confirms what I have been claiming since years: aside from its incredible products such as the Weobottle (we-o.com) and a series of products for the BtoB or BtoC markets, Weo is a profound change in the way the world will consume water. This vision is animating Weo’s team to offer a healthier future. Link to the published paper: https://lnkd.in/epY9KURq Proud of our research team on this paper: Brenda Court Vasquez  Shirley Ann Arroyo Dr. Kelly Halderman Lara R Nyman, PhD Jonathan Poli #antiaging #senescence #innovation #Weo #health #biotech #healthtech #watertech #longevity #lifespan  Weo Weo Foundation https://lnkd.in/epY9KURq

54

15 Comments

Knock knock ! Who’s there? BGene ! BGene who? BGene Genetics’ new website ! Come take a look and explore the synergistic interplay between biotechnology and computer modelling for sustainable innovations: https://bgene.fr/en #BGene #Innovation #yourRDpartner #synbio #biotechnology #sustainability

24

1 Comment

"When To License vs. Buy the Whole Pig" - BioSpace opinion piece by Annalee Armstrong. A very nicely written perspective on Pharma : Biotech transactions. It is better for pharma to commit to smaller upfronts and load larger backend milestones, especially when therapeutics are novel and potentially risky. With regards to upfronts Armstrong writes - " The back-loaded nature of these deals “shift[s] all the risk back [to] the person innovating,” Spoor said, making these types of deals attractive for pharma companies looking to access early candidates that have yet to show commercial success. When a licensing deal is announced, Spoor said he eyes the upfront payment to see “how much is real, how much is future potential.” According to GlobalData, upfront payments are slowly getting bigger, growing 137%, or $55 million on average from 2021 to 2024, or 22% ($17 million) per year. " However an acquisition may be better to eliminate competition from the field, an example cited is Pfizer buying Seagen to establish a massive footprint in the ADC space. Nice short read on the current practices of biotech economics. BioSpace article here - https://lnkd.in/eMc7qDW9

88

9 Comments